StocksMediumUpdated•Originally published 18 November 2026•Updated 18 November 2026•
1 min read
Apimeds Pharmaceuticals US Reports $7.68 GAAP EPS and $2.89M Revenue in Q3
Key Facts
1Apimeds Pharmaceuticals US reported quarterly revenue of $2.89 million.
2The company achieved operating income of $2.0 million as it completes its transition to a technology infrastructure business.
Apimeds Pharmaceuticals US reported a GAAP EPS of $7.68 for the third quarter of 2026. GlobeNewswire reported that the company generated quarterly revenue of $2.89 million, while operating income reached $2.0 million.
These results mark the company's first operating revenue since initiating its strategic pivot toward technology infrastructure services. APUS was trading at $1.95 on November 17, 2026, after fluctuating between a session low of $1.84 and a high of $2.04.